Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome

Prema Peethambaram, Brooke L. Fridley, Robert A. Vierkant, Melissa C. Larson, Kimberly R. Kalli, Elaine A. Elliott, Ann L Oberg, Kristin L. White, David N. Rider, Gary Keeney, Julie M Cunningham, Lynn C. Hartmann, Ellen L Goode

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Using the most comprehensive approach to selecting polymorphisms to date, we sought to examine whether time to recurrence in ovarian cancer was associated with common inherited variation in eight genes involved in drug metabolism, multi-drug resistance, or DNA repair, namely ABCB1, CYP2C8, CYP3A4, ERCC1, ERCC2, GSTM1, XPC, and XRCC1. Invasive epithelial ovarian cancer patients (N=445) seen at the Mayo Clinic from 1999 to 2009 with 275 observed recurrences or deaths were analyzed at 94 SNPs in these candidate genes. Cox regression was used to estimate hazard ratios and 95% confidence intervals for each single nucleotide polymorphism (SNP) and outcome (defined as time to recurrence or death). Analyses were conducted at the gene level and on case subsets defined by histopathology and chemotherapeutic agent. At ABCB1, minor alleles at several SNPs were associated with outcome, with the most significant being the intronic SNP rs12334183 (HR=0.65, 95% CI 0.51-0.83; p=0.0005). Overall variation in ABCB1 was predictive of outcome as well (p=0.003). At ERCC2, minor alleles at several SNPs were associated with outcome among women with high-grade serous disease (e.g., rs238417, HR 0.74, 95% CI 0.59-0.92; p=0.006). No associations with outcome were observed in GSTM1, CYP2C8, CYP3A4, ERCC1, XPC, or XRCC1. In summary, inherited variation in ABCB1 and ERCC2 was associated with outcome in patients with ovarian cancer seen at the Mayo Clinic. As the associated SNPs have not been studied previously in ovarian cancer, these findings suggest novel sites of variation which may, in part, explain the range of treatment responses seen in this disease.

Original languageEnglish (US)
Pages (from-to)185-195
Number of pages11
JournalInternational Journal of Molecular Epidemiology and Genetics
Volume2
Issue number2
StatePublished - 2011

Fingerprint

Ovarian Neoplasms
Single Nucleotide Polymorphism
Cytochrome P-450 CYP3A
Recurrence
Alleles
Genes
Multiple Drug Resistance
DNA Repair
Confidence Intervals
Pharmaceutical Preparations
Cytochrome P-450 CYP2C8

Keywords

  • Drug-related variants
  • Metabolism
  • Ovarian cancer

ASJC Scopus subject areas

  • Epidemiology
  • Genetics(clinical)
  • Genetics

Cite this

Peethambaram, P., Fridley, B. L., Vierkant, R. A., Larson, M. C., Kalli, K. R., Elliott, E. A., ... Goode, E. L. (2011). Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. International Journal of Molecular Epidemiology and Genetics, 2(2), 185-195.

Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. / Peethambaram, Prema; Fridley, Brooke L.; Vierkant, Robert A.; Larson, Melissa C.; Kalli, Kimberly R.; Elliott, Elaine A.; Oberg, Ann L; White, Kristin L.; Rider, David N.; Keeney, Gary; Cunningham, Julie M; Hartmann, Lynn C.; Goode, Ellen L.

In: International Journal of Molecular Epidemiology and Genetics, Vol. 2, No. 2, 2011, p. 185-195.

Research output: Contribution to journalArticle

Peethambaram, P, Fridley, BL, Vierkant, RA, Larson, MC, Kalli, KR, Elliott, EA, Oberg, AL, White, KL, Rider, DN, Keeney, G, Cunningham, JM, Hartmann, LC & Goode, EL 2011, 'Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome', International Journal of Molecular Epidemiology and Genetics, vol. 2, no. 2, pp. 185-195.
Peethambaram P, Fridley BL, Vierkant RA, Larson MC, Kalli KR, Elliott EA et al. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. International Journal of Molecular Epidemiology and Genetics. 2011;2(2):185-195.
Peethambaram, Prema ; Fridley, Brooke L. ; Vierkant, Robert A. ; Larson, Melissa C. ; Kalli, Kimberly R. ; Elliott, Elaine A. ; Oberg, Ann L ; White, Kristin L. ; Rider, David N. ; Keeney, Gary ; Cunningham, Julie M ; Hartmann, Lynn C. ; Goode, Ellen L. / Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. In: International Journal of Molecular Epidemiology and Genetics. 2011 ; Vol. 2, No. 2. pp. 185-195.
@article{ea3d1045302b4cffb0eff14d78b3d738,
title = "Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome",
abstract = "Using the most comprehensive approach to selecting polymorphisms to date, we sought to examine whether time to recurrence in ovarian cancer was associated with common inherited variation in eight genes involved in drug metabolism, multi-drug resistance, or DNA repair, namely ABCB1, CYP2C8, CYP3A4, ERCC1, ERCC2, GSTM1, XPC, and XRCC1. Invasive epithelial ovarian cancer patients (N=445) seen at the Mayo Clinic from 1999 to 2009 with 275 observed recurrences or deaths were analyzed at 94 SNPs in these candidate genes. Cox regression was used to estimate hazard ratios and 95{\%} confidence intervals for each single nucleotide polymorphism (SNP) and outcome (defined as time to recurrence or death). Analyses were conducted at the gene level and on case subsets defined by histopathology and chemotherapeutic agent. At ABCB1, minor alleles at several SNPs were associated with outcome, with the most significant being the intronic SNP rs12334183 (HR=0.65, 95{\%} CI 0.51-0.83; p=0.0005). Overall variation in ABCB1 was predictive of outcome as well (p=0.003). At ERCC2, minor alleles at several SNPs were associated with outcome among women with high-grade serous disease (e.g., rs238417, HR 0.74, 95{\%} CI 0.59-0.92; p=0.006). No associations with outcome were observed in GSTM1, CYP2C8, CYP3A4, ERCC1, XPC, or XRCC1. In summary, inherited variation in ABCB1 and ERCC2 was associated with outcome in patients with ovarian cancer seen at the Mayo Clinic. As the associated SNPs have not been studied previously in ovarian cancer, these findings suggest novel sites of variation which may, in part, explain the range of treatment responses seen in this disease.",
keywords = "Drug-related variants, Metabolism, Ovarian cancer",
author = "Prema Peethambaram and Fridley, {Brooke L.} and Vierkant, {Robert A.} and Larson, {Melissa C.} and Kalli, {Kimberly R.} and Elliott, {Elaine A.} and Oberg, {Ann L} and White, {Kristin L.} and Rider, {David N.} and Gary Keeney and Cunningham, {Julie M} and Hartmann, {Lynn C.} and Goode, {Ellen L}",
year = "2011",
language = "English (US)",
volume = "2",
pages = "185--195",
journal = "International Journal of Molecular Epidemiology and Genetics",
issn = "1948-1756",
publisher = "e-Century Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome

AU - Peethambaram, Prema

AU - Fridley, Brooke L.

AU - Vierkant, Robert A.

AU - Larson, Melissa C.

AU - Kalli, Kimberly R.

AU - Elliott, Elaine A.

AU - Oberg, Ann L

AU - White, Kristin L.

AU - Rider, David N.

AU - Keeney, Gary

AU - Cunningham, Julie M

AU - Hartmann, Lynn C.

AU - Goode, Ellen L

PY - 2011

Y1 - 2011

N2 - Using the most comprehensive approach to selecting polymorphisms to date, we sought to examine whether time to recurrence in ovarian cancer was associated with common inherited variation in eight genes involved in drug metabolism, multi-drug resistance, or DNA repair, namely ABCB1, CYP2C8, CYP3A4, ERCC1, ERCC2, GSTM1, XPC, and XRCC1. Invasive epithelial ovarian cancer patients (N=445) seen at the Mayo Clinic from 1999 to 2009 with 275 observed recurrences or deaths were analyzed at 94 SNPs in these candidate genes. Cox regression was used to estimate hazard ratios and 95% confidence intervals for each single nucleotide polymorphism (SNP) and outcome (defined as time to recurrence or death). Analyses were conducted at the gene level and on case subsets defined by histopathology and chemotherapeutic agent. At ABCB1, minor alleles at several SNPs were associated with outcome, with the most significant being the intronic SNP rs12334183 (HR=0.65, 95% CI 0.51-0.83; p=0.0005). Overall variation in ABCB1 was predictive of outcome as well (p=0.003). At ERCC2, minor alleles at several SNPs were associated with outcome among women with high-grade serous disease (e.g., rs238417, HR 0.74, 95% CI 0.59-0.92; p=0.006). No associations with outcome were observed in GSTM1, CYP2C8, CYP3A4, ERCC1, XPC, or XRCC1. In summary, inherited variation in ABCB1 and ERCC2 was associated with outcome in patients with ovarian cancer seen at the Mayo Clinic. As the associated SNPs have not been studied previously in ovarian cancer, these findings suggest novel sites of variation which may, in part, explain the range of treatment responses seen in this disease.

AB - Using the most comprehensive approach to selecting polymorphisms to date, we sought to examine whether time to recurrence in ovarian cancer was associated with common inherited variation in eight genes involved in drug metabolism, multi-drug resistance, or DNA repair, namely ABCB1, CYP2C8, CYP3A4, ERCC1, ERCC2, GSTM1, XPC, and XRCC1. Invasive epithelial ovarian cancer patients (N=445) seen at the Mayo Clinic from 1999 to 2009 with 275 observed recurrences or deaths were analyzed at 94 SNPs in these candidate genes. Cox regression was used to estimate hazard ratios and 95% confidence intervals for each single nucleotide polymorphism (SNP) and outcome (defined as time to recurrence or death). Analyses were conducted at the gene level and on case subsets defined by histopathology and chemotherapeutic agent. At ABCB1, minor alleles at several SNPs were associated with outcome, with the most significant being the intronic SNP rs12334183 (HR=0.65, 95% CI 0.51-0.83; p=0.0005). Overall variation in ABCB1 was predictive of outcome as well (p=0.003). At ERCC2, minor alleles at several SNPs were associated with outcome among women with high-grade serous disease (e.g., rs238417, HR 0.74, 95% CI 0.59-0.92; p=0.006). No associations with outcome were observed in GSTM1, CYP2C8, CYP3A4, ERCC1, XPC, or XRCC1. In summary, inherited variation in ABCB1 and ERCC2 was associated with outcome in patients with ovarian cancer seen at the Mayo Clinic. As the associated SNPs have not been studied previously in ovarian cancer, these findings suggest novel sites of variation which may, in part, explain the range of treatment responses seen in this disease.

KW - Drug-related variants

KW - Metabolism

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=79958160457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958160457&partnerID=8YFLogxK

M3 - Article

C2 - 21686133

AN - SCOPUS:79958160457

VL - 2

SP - 185

EP - 195

JO - International Journal of Molecular Epidemiology and Genetics

JF - International Journal of Molecular Epidemiology and Genetics

SN - 1948-1756

IS - 2

ER -